EP300 and cancer: This phosphorylation enables SQSTM1/p62‐mediated recognition and autophagic degradation of MITF, thereby inhibiting the progression of ESCC.[5] Furthermore, MITF can be acetylated by the p300/CREB‐binding protein, which supports the development of melanocytes and drives tumorigenesis.[48] These modifications, along with the sumoylation of MITF by SUMO3, highlight a critical and distinct regulatory mechanism in controlling MITF stability and function across various cancer types.